Abstract
Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ageing population, cardiovascular disease and medication non-adherence are likely to become increasingly prevalent. Multiple methods for detecting non-adherence exist but are imperfect, and, despite emerging technology, a gold standard remains elusive. Non-adherence to medication is dynamic and often has multiple causes, particularly in the context of cardiovascular disease, which tends to require lifelong medication to control symptoms and risk factors in order to prevent disease progression. In this Review, we identify the causes of medication non-adherence and summarize interventions that have been proven in randomized clinical trials to be effective in improving adherence. Practical solutions and areas for future research are also proposed.
Key points
-
Medication non-adherence remains a global health problem that is not fully appreciated and is under-addressed in the clinic.
-
The label of being ‘non-adherent to medications’ is often considered in a binary (and pejorative) manner; however, medication-taking behaviour is a complicated process with multiple phases and potential barriers.
-
Several methods for detecting non-adherence exist, with many providing complementary rather than gold-standard information.
-
Clinicians need to understand the importance of simplifying medication regimens and encouraging the use of blister packs, whereas health systems need to explore multifaceted, multidisciplinary interventions for complex non-adherence.
-
Multiple interventions for improving medication adherence have proven efficacy, but a one-size-fits-all solution is unlikely to be successful; both precision and population approaches are required and need further evaluation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795–808 (2020).
Naderi, S. H., Bestwick, J. P. & Wald, D. S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 125, 882–887.e1 (2012).
Bansilal, S. et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J. Am. Coll. Cardiol. 68, 789–801 (2016).
Du, L., Cheng, Z., Zhang, Y., Li, Y. & Mei, D. The impact of medication adherence on clinical outcomes of coronary artery disease: a meta-analysis. Eur. J. Prev. Cardiol. 24, 962–970 (2017).
Garcia, R. A. et al. Association of medication adherence with health outcomes in the ISCHEMIA trial. J. Am. Coll. Cardiol. 80, 755–765 (2022).
Ho, P. M. et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J. 155, 772–779 (2008).
Jackevicius, C. A., Mamdani, M. & Tu, J. V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288, 462–467 (2002).
Rasmussen, J. N., Chong, A. & Alter, D. A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297, 177–186 (2007).
Lloyd, J. T., Maresh, S., Powers, C. A., Shrank, W. H. & Alley, D. E. How much does medication nonadherence cost the Medicare Fee-for-Service program? Med. Care 57, 218–224 (2019).
McDermott, M. M., Schmitt, B. & Wallner, E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch. Intern. Med. 157, 1921–1929 (1997).
Simpson, S. H. et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333, 15 (2006).
Pan American Health Organization. Regional Office for the Americas of the World Health Organization. Adherence to Long-term Therapies: Evidence for Action, 2003 https://www.paho.org/en/documents/who-adherence-long-term-therapies-evidence-action-2003 (2003).
Vrijens, B. et al. A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol. 73, 691–705 (2012).
Raebel, M. A., Schmittdiel, J., Karter, A. J., Konieczny, J. L. & Steiner, J. F. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med. Care 51, S11–S21 (2013).
Franklin, J. M. et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med. Care 51, 789–796 (2013).
Thorpe, C. T., Bryson, C. L., Maciejewski, M. L. & Bosworth, H. B. Medication acquisition and self-reported adherence in veterans with hypertension. Med. Care 47, 474–481 (2009).
Osterberg, L. & Blaschke, T. Adherence to medication. N. Engl. J. Med. 353, 487–497 (2005).
Meddings, J., Kerr, E. A., Heisler, M. & Hofer, T. P. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv. Res. 12, 270 (2012).
Morisky, D. E., Ang, A., Krousel-Wood, M. & Ward, H. J. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. 10, 348–354 (2008).
Tegegn, H. G., Wark, S., Tursan d’Espaignet, E. & Spark, M. J. Measurement properties of patient-reported outcome measures for medication adherence in cardiovascular disease: a COSMIN systematic review. Clin. Drug Investig. 42, 879–908 (2022).
Kim, C. J. et al. Evaluation of the measurement properties of self-reported medication adherence instruments among people at risk for metabolic syndrome: a systematic review. Diabetes Educ. 42, 618–634 (2016).
Kwan, Y. H. et al. Measurement properties of existing patient-reported outcome measures on medication adherence: systematic review. J. Med. Internet Res. 22, e19179 (2020).
Lane, D. et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension 79, 12–23 (2022).
Unger, T. et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension 75, 1334–1357 (2020).
Berra, E. et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension 68, 297–306 (2016).
Lane, D., Patel, P., Khunti, K. & Gupta, P. Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. Patient Prefer. Adherence 13, 537–547 (2019).
Chai, P. R. et al. Utilizing an ingestible biosensor to assess real-time medication adherence. J. Med. Toxicol. 11, 439–444 (2015).
de Miguel Beriain, I. & Morla Gonzalez, M. ‘Digital pills’ for mental diseases: an ethical and social analysis of the issues behind the concept. J. Law Biosci. 7, lsaa040 (2020).
Cosgrove, L., Cristea, I. A., Shaughnessy, A. F., Mintzes, B. & Naudet, F. Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. BMJ Evid. Based Med. 24, 231–238 (2019).
Coleman, C. I. et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr. Med. Res. Opin. 28, 669–680 (2012).
Marazzi, G. et al. Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: the ALL-IN-ONE trial. Int. J. Cardiol. 222, 885–887 (2016).
Parati, G., Kjeldsen, S., Coca, A., Cushman, W. C. & Wang, J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension 77, 692–705 (2021).
Wald, N. J. & Law, M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419–1423 (2003).
Munoz, D. et al. Polypill for cardiovascular disease prevention in an underserved population. N. Engl. J. Med. 381, 1114–1123 (2019).
Rao, S. et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials. Prog. Cardiovasc. Dis. 73, 48–55 (2022).
Castellano, J. M. et al. A polypill strategy to improve adherence: results from the FOCUS project. J. Am. Coll. Cardiol. 64, 2071–2082 (2014).
Patel, A. et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur. J. Prev. Cardiol. 22, 920–930 (2015).
Roshandel, G. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672–683 (2019).
Selak, V. et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 348, g3318 (2014).
Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).
Castellano, J. M. et al. Polypill strategy in secondary cardiovascular prevention. N. Engl. J. Med. 387, 967–977 (2022).
Choudhry, N. K. et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch. Intern. Med. 171, 814–822 (2011).
Ross, A., Jami, H., Young, H. A. & Katz, R. Sync and swim: the impact of medication consolidation on adherence in Medicaid patients. J. Prim. Care Commun. Health 4, 240–244 (2013).
Agarwal, S. et al. Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy? Am. J. Ther. 16, 119–126 (2009).
Delate, T., Fairman, K. A., Carey, S. M. & Motheral, B. R. Randomized controlled trial of a dose consolidation program. J. Manag. Care Pharm. 10, 396–403 (2004).
Nsiah, I. et al. The impact of medication synchronization programs on medication adherence: a meta-analysis. J. Am. Pharm. Assoc. 61, e202–e211 (2021).
Neil, W. P., Shiokari, C. E., Burchette, R. J., Stapleton, D. & Ovbiagele, B. Mail order pharmacy use and adherence to secondary prevention drugs among stroke patients. J. Neurol. Sci. 390, 117–120 (2018).
Rymer, J. A. et al. Difference in medication adherence between patients prescribed a 30-day versus 90-day supply after acute myocardial infarction. J. Am. Heart Assoc. 10, e016215 (2021).
Bosworth, H. B. et al. Evaluation of a packaging approach to improve cholesterol medication adherence. Am. J. Manag. Care 23, e280–e286 (2017).
Zedler, B. K., Kakad, P., Colilla, S., Murrelle, L. & Shah, N. R. Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review. Clin. Ther. 33, 62–73 (2011).
Conn, V. S. et al. Packaging interventions to increase medication adherence: systematic review and meta-analysis. Curr. Med. Res. Opin. 31, 145–160 (2015).
Mahtani, K. R., Heneghan, C. J., Glasziou, P. P. & Perera, R. Reminder packaging for improving adherence to self-administered long-term medications.Cochrane Database Syst. Rev. 1, CD005025 (2006).
Tan, B. Y., Shafie, A. A., Hassali, M. A. A. & Saleem, F. Assessment of medication adherence and the costs associated with a calendar blister pack intervention among hypertensive patients in Malaysia: a randomized controlled trial. SAGE Open Med. 5, 2050312117709189 (2017).
Izzah, Z., Zijp, T. R., Aberg, C., Touw, D. J. & van Boven, J. F. M. Electronic smart blister packages to monitor and support medication adherence: a usability study. Patient Prefer. Adherence 16, 2543–2558 (2022).
Muhlfeld, L., Langguth, P., Hausler, H. & Hagels, H. Influence of blister package design on usability among older adults. Int. J. Clin. Pharm. 34, 553–560 (2012).
Miller, W. R. & Rollnick, S. Ten things that motivational interviewing is not. Behav. Cogn. Psychother. 37, 129–140 (2009).
Papus, M. et al. Motivational interviewing to support medication adherence in adults with chronic conditions: systematic review of randomized controlled trials. Patient Educ. Couns. 105, 3186–3203 (2022).
Mohan, A. et al. A motivational interviewing intervention to improve adherence to ACEIs/ARBs among nonadherent older adults with comorbid hypertension and diabetes. Drugs Aging 40, 377–390 (2023).
Ogedegbe, G. et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am. J. Hypertens. 21, 1137–1143 (2008).
Wu, J. R., Corley, D. J., Lennie, T. A. & Moser, D. K. Effect of a medication-taking behavior feedback theory-based intervention on outcomes in patients with heart failure. J. Card. Fail. 18, 1–9 (2012).
Barker-Collo, S. et al. Improving adherence to secondary stroke prevention strategies through motivational interviewing: randomized controlled trial. Stroke 46, 3451–3458 (2015).
Damush, T. M. et al. The effect of a locally adapted, secondary stroke risk factor self-management program on medication adherence among veterans with stroke/TIA. Transl. Behav. Med. 6, 457–468 (2016).
O’Carroll, R. E., Chambers, J. A., Dennis, M., Sudlow, C. & Johnston, M. Improving adherence to medication in stroke survivors: a pilot randomised controlled trial. Ann. Behav. Med. 46, 358–368 (2013).
Abughosh, S. M. et al. Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence. J. Manag. Care Spec. Pharm. 25, 1053–1062 (2019).
Volpp, K. G. et al. A randomized, controlled trial of financial incentives for smoking cessation. N. Engl. J. Med. 360, 699–709 (2009).
Li, R. et al. The nudge strategies for weight loss in adults with obesity and overweight: a systematic review and meta-analysis. Health Policy 125, 1527–1535 (2021).
Horne, B. D. et al. Behavioral nudges as patient decision support for medication adherence: the ENCOURAGE randomized controlled trial. Am. Heart J. 244, 125–134 (2022).
Zambroski, C. H., Moser, D. K., Bhat, G. & Ziegler, C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur. J. Cardiovasc. Nurs. 4, 198–206 (2005).
Barnes, S. et al. Communication in heart failure: perspectives from older people and primary care professionals. Health Soc. Care Commun. 14, 482–490 (2006).
Ekman, I., Schaufelberger, M., Kjellgren, K. I., Swedberg, K. & Granger, B. B. Standard medication information is not enough: poor concordance of patient and nurse perceptions. J. Adv. Nurs. 60, 181–186 (2007).
Tarn, D. M. et al. Physician communication when prescribing new medications. Arch. Intern. Med. 166, 1855–1862 (2006).
Turkson-Ocran, R. N., Ogunwole, S. M., Hines, A. L. & Peterson, P. N. Shared decision making in cardiovascular patient care to address cardiovascular disease disparities. J. Am. Heart Assoc. 10, e018183 (2021).
Noseworthy, P. A. et al. Effect of shared decision-making for stroke prevention on treatment adherence and safety outcomes in patients with atrial fibrillation: a randomized clinical trial. J. Am. Heart Assoc. 11, e023048 (2022).
Cramer, J. A., Scheyer, R. D. & Mattson, R. H. Compliance declines between clinic visits. Arch. Intern. Med. 150, 1509–1510 (1990).
Reddy, A. et al. Patient and partner feedback reports to improve statin medication adherence: a randomized control trial. J. Gen. Intern. Med. 32, 256–261 (2017).
Tan, J. P., Cheng, K. K. F. & Siah, R. C. A systematic review and meta-analysis on the effectiveness of education on medication adherence for patients with hypertension, hyperlipidaemia and diabetes. J. Adv. Nurs. 75, 2478–2494 (2019).
Morgado, M., Rolo, S. & Castelo-Branco, M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int. J. Clin. Pharm. 33, 132–140 (2011).
Wu, Q. et al. Effects of transitional health management on adherence and prognosis in elderly patients with acute myocardial infarction in percutaneous coronary intervention: a cluster randomized controlled trial. PLoS One 14, e0217535 (2019).
Chen, C. et al. Post-discharge short message service improves short-term clinical outcome and self-care behaviour in chronic heart failure. Esc. Heart Fail. 6, 164–173 (2019).
Rinfret, S. et al. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart 99, 562–569 (2013).
Ampofo, A. G., Khan, E. & Ibitoye, M. B. Understanding the role of educational interventions on medication adherence in hypertension: a systematic review and meta-analysis. Heart Lung 49, 537–547 (2020).
Eussen, S. R. et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Ann. Pharmacother. 44, 1905–1913 (2010).
Ha Dinh, T. T., Bonner, A., Clark, R., Ramsbotham, J. & Hines, S. The effectiveness of the teach-back method on adherence and self-management in health education for people with chronic disease: a systematic review. JBI Database Syst. Rev. Implement. Rep. 14, 210–247 (2016).
Nieuwkerk, P. T. et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am. J. Cardiol. 110, 666–672 (2012).
Paasche-Orlow, M. K., Parker, R. M., Gazmararian, J. A., Nielsen-Bohlman, L. T. & Rudd, R. R. The prevalence of limited health literacy. J. Gen. Intern. Med. 20, 175–184 (2005).
Kripalani, S., Schmotzer, B. & Jacobson, T. A. Improving medication adherence through graphically enhanced interventions in coronary heart disease (IMAGE-CHD): a randomized controlled trial. J. Gen. Intern. Med. 27, 1609–1617 (2012).
Rabbani, M. et al. Towards developing a voice-activated self-monitoring application (VoiS) for adults with diabetes and hypertension. Proc. COMPSAC 2022, 512–519 (2022).
Derose, S. F. et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern. Med. 173, 38–43 (2013).
Fischer, M. A. et al. A randomized telephone intervention trial to reduce primary medication nonadherence. J. Manag. Care Spec. Pharm. 21, 124–131 (2015).
Adler, A. J. et al. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 4, CD011851 (2017).
Thakkar, J. et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern. Med. 176, 340–349 (2016).
Pandey, A., Krumme, A. A., Patel, T. & Choudhry, N. K. The impact of text messaging on medication adherence and exercise among postmyocardial infarction patients: randomized controlled pilot trial. JMIR mHealth uHealth 5, e110 (2017).
Park, L. G., Howie-Esquivel, J., Chung, M. L. & Dracup, K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ. Couns. 94, 261–268 (2014).
Quilici, J. et al. Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. Int. J. Cardiol. 168, 568–569 (2013).
Bermon, A. et al. Efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: TXT2HEART Colombia randomized controlled trial. JMIR mHealth uHealth 9, e25548 (2021).
Chow, C. K. et al. Text messages to improve medication adherence and secondary prevention after acute coronary syndrome: the TEXTMEDS randomized clinical trial. Circulation 145, 1443–1455 (2022).
Maddison, R. et al. An intervention to improve medication adherence in people with heart disease (Text4HeartII): randomized controlled trial. JMIR mHealth uHealth 9, e24952 (2021).
Klimis, H. et al. Text message analysis using machine learning to assess predictors of engagement with mobile health chronic disease prevention programs: content analysis. JMIR mHealth uHealth 9, e27779 (2021).
Bobrow, K. et al. Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS-Text Adherence Support [StAR]): a single-blind, randomized trial. Circulation 133, 592–600 (2016).
Vervloet, M. et al. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with type 2 diabetes: evidence from a randomized controlled trial. Diabet. Med. 31, 821–828 (2014).
Aitken M, Nass D. Digital Health Trends 2021: Innovation, Evidence, Regulation, and Adoption. IQVIA Institute https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/digital-health-trends-2021 (2023).
Al-Arkee, S. et al. Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis. J. Med. Internet Res. 23, e24190 (2021).
Armitage, L. C., Kassavou, A. & Sutton, S. Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis. BMJ Open 10, e032045 (2020).
Gandapur, Y. et al. The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. Eur. Heart J. Qual. Care Clin. Outcomes 2, 237–244 (2016).
Burke, L. E. et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation 132, 1157–1213 (2015).
Heldenbrand, S. et al. Assessment of medication adherence app features, functionality, and health literacy level and the creation of a searchable Web-based adherence app resource for health care professionals and patients. J. Am. Pharm. Assoc. 56, 293–302 (2016).
Etminani, K., Tao Engström, A., Göransson, C., Sant’Anna, A. & Nowaczyk, S. How behavior change strategies are used to design digital interventions to improve medication adherence and blood pressure among patients with hypertension: systematic review. J. Med. Internet Res. 22, e17201 (2020).
Zaugg, V., Korb-Savoldelli, V., Durieux, P. & Sabatier, B. Providing physicians with feedback on medication adherence for people with chronic diseases taking long-term medication. Cochrane Database Syst. Rev. 1, CD012042 (2018).
Kronish, I. M. et al. An electronic adherence measurement intervention to reduce clinical inertia in the treatment of uncontrolled hypertension: the MATCH cluster randomized clinical trial. J. Gen. Intern. Med. 31, 1294–1300 (2016).
Pladevall, M., Divine, G., Wells, K. E., Resnicow, K. & Williams, L. K. A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educ. 41, 136–146 (2015).
Tamblyn, R. et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med. Decis. Mak. 30, 176–188 (2010).
Willis, J. M. et al. Decision support for evidence-based pharmacotherapy detects adherence problems but does not impact medication use. Stud. Health Technol. Inf. 183, 116–125 (2013).
Asch, D. A. et al. Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA 314, 1926–1935 (2015).
Riegel, B., Stephens-Shields, A., Jaskowiak-Barr, A., Daus, M. & Kimmel, S. E. A behavioral economics-based telehealth intervention to improve aspirin adherence following hospitalization for acute coronary syndrome. Pharmacoepidemiol. Drug Saf. 29, 513–517 (2020).
Owolabi, M. O. et al. Randomized trial of an intervention to improve blood pressure control in stroke survivors. Circ. Cardiovasc. Qual. Outcomes 12, e005904 (2019).
VanEpps, E. M. et al. Financial incentives for chronic disease management: results and limitations of 2 randomized clinical trials with New York Medicaid patients. Am. J. Health Promot. 32, 1537–1543 (2018).
Zheng, L. et al. Effect of financial incentives on hypertension control: a multicenter randomized controlled trial in China. Hypertension 79, 2202–2211 (2022).
Kaiser Family Foundation. KFF Health Tracking Poll 2019: Health Care Policy In Congress And On The Campaign Trail https://www.kff.org/health-reform/poll-finding/kff-health-tracking-poll-september-2019/ (2019).
Doshi, J. A., Zhu, J., Lee, B. Y., Kimmel, S. E. & Volpp, K. G. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 119, 390–397 (2009).
Hsu, J. et al. Unintended consequences of caps on Medicare drug benefits. N. Engl. J. Med. 354, 2349–2359 (2006).
Hung, A. et al. Impact of financial medication assistance on medication adherence: a systematic review. J. Manag. Care Spec. Pharm. 27, 924–935 (2021).
Choudhry, N. K. et al. Full coverage for preventive medications after myocardial infarction. N. Engl. J. Med. 365, 2088–2097 (2011).
Wang, T. Y. et al. Effect of medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial. JAMA 321, 44–55 (2019).
Marrs, J. C. & Saseen, J. J. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients. Pharmacotherapy 28, 562–569 (2008).
Schoen, M. D., DiDomenico, R. J., Connor, S. E., Dischler, J. E. & Bauman, J. L. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy 21, 1455–1463 (2001).
Choudhry, N. K. et al. Effect of a remotely delivered tailored multicomponent approach to enhance medication taking for patients with hyperlipidemia, hypertension, and diabetes: the STIC2IT cluster randomized clinical trial. JAMA Intern. Med. 178, 1182–1189 (2018).
Ho, P. M. et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch. Intern. Med. 166, 1836–1841 (2006).
Lee, J. K., Grace, K. A. & Taylor, A. J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 296, 2563–2571 (2006).
Obreli-Neto, P. R. et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int. J. Clin. Pharm. 33, 642–649 (2011).
Svarstad, B. L. et al. Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. J. Am. Pharm. Assoc. 53, 520–529 (2013).
Crowley, M. J. et al. The Cholesterol, Hypertension, And Glucose Education (CHANGE) study: results from a randomized controlled trial in African Americans with diabetes. Am. Heart J. 166, 179–186 (2013).
Granger, B. B. et al. Results of the chronic heart failure intervention to improve medication adherence study: a randomized intervention in high-risk patients. Am. Heart J. 169, 539–548 (2015).
Xavier, D. et al. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes Endocrinol. 4, 244–253 (2016).
Reeves, L. et al. Pharmacist interventions in the management of blood pressure control and adherence to antihypertensive medications: a systematic review of randomized controlled trials. J. Pharm. Pract. 34, 480–492 (2021).
Onatibia-Astibia, A., Malet-Larrea, A., Gastelurrutia, M. A., Calvo, B. & Goyenechea, E. Community pharmacist interventions to improve adherence to lipid lowering medication and their influence on clinical outcomes: a systematic review and meta-analysis. J. Eval. Clin. Pract. 27, 451–463 (2021).
Schumacher, P. M. et al. The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. Esc. Heart Fail. 8, 3566–3576 (2021).
Ho, P. M. et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern. Med. 174, 186–193 (2014).
Lin, C. Y. et al. Can a multifaceted intervention including motivational interviewing improve medication adherence, quality of life, and mortality rates in older patients undergoing coronary artery bypass surgery? A multicenter, randomized controlled trial with 18-month follow-up. Drugs Aging 34, 143–156 (2017).
Murray, M. D. et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann. Intern. Med. 146, 714–725 (2007).
Ostbring, M. J., Eriksson, T., Petersson, G. & Hellstrom, L. Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial. BMC Cardiovasc. Disord. 21, 367 (2021).
Pladevall, M. et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). Circulation 122, 1183–1191 (2010).
Schulz, M. et al. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. Eur. J. Heart Fail. 21, 1012–1021 (2019).
Stewart, K. et al. A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial). J. Clin. Pharm. Ther. 39, 527–534 (2014).
Wong, M. C. et al. Effectiveness of a pharmacist-led drug counseling on enhancing antihypertensive adherence and blood pressure control: a randomized controlled trial. J. Clin. Pharmacol. 53, 753–761 (2013).
Bouvy, M. L. et al. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J. Card. Fail. 9, 404–411 (2003).
NHS. NHS New Medicine Service https://www.england.nhs.uk/primary-care/pharmacy/nhs-new-medicine-service/ (2023).
Elliott, R. A. et al. ’New Medicine Service’: supporting adherence in people starting a new medication for a long-term condition: 26-week follow-up of a pragmatic randomised controlled trial. BMJ Qual. Saf. 29, 286–295 (2020).
Jacob, V. et al. Pharmacist interventions for medication adherence: community guide economic reviews for cardiovascular disease. Am. J. Prev. Med. 62, e202–e222 (2022).
Dickson, V. V., Knafl, G. J. & Riegel, B. Predictors of medication nonadherence differ among black and white patients with heart failure. Res. Nurs. Health 38, 289–300 (2015).
Zhang, Y. & Baik, S. H. Race/ethnicity, disability, and medication adherence among medicare beneficiaries with heart failure. J. Gen. Intern. Med. 29, 602–607 (2014).
Wu, J. R., Moser, D. K., Chung, M. L. & Lennie, T. A. Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure. J. Card. Fail. 14, 203–210 (2008).
Brown, C. M. & Segal, R. Ethnic differences in temporal orientation and its implications for hypertension management. J. Health Soc. Behav. 37, 350–361 (1996).
Chang, T. J. et al. Association between patient-clinician relationships and adherence to antihypertensive medications among black adults: an observational study design. J. Am. Heart Assoc. 10, e019943 (2021).
Daugherty, S. L. et al. Using values affirmation to reduce the effects of stereotype threat on hypertension disparities: protocol for the multicenter randomized hypertension and values (HYVALUE) trial. JMIR Res. Protoc. 8, e12498 (2019).
Daugherty, S. L. et al. Effect of values affirmation on reducing racial differences in adherence to hypertension medication: the HYVALUE randomized clinical trial. JAMA Netw. Open. 4, e2139533 (2021).
Ruppar, T. M., Dunbar-Jacob, J. M., Mehr, D. R., Lewis, L. & Conn, V. S. Medication adherence interventions among hypertensive black adults: a systematic review and meta-analysis. J. Hypertens. 35, 1145–1154 (2017).
Adachi, T., Tsunekawa, Y. & Tanimura, D. Association between the Big Five personality traits and medication adherence in patients with cardiovascular disease: a cross-sectional study. PLoS One 17, e0278534 (2022).
Craig, L. S. et al. Implicit and explicit attitudes toward antihypertensive medications explain variation in pharmacy refill and self-reported adherence beyond traditional risk factors: potential novel mechanism underlying adherence. J. Am. Heart Assoc. 10, e018986 (2021).
Hogervorst, S. et al. Scalability of effective adherence interventions for patients using cardiovascular disease medication: a realist synthesis-inspired systematic review. Br. J. Clin. Pharmacol. 89, 1996–2019 (2023).
Zullig, L. L., Deschodt, M., Liska, J., Bosworth, H. B. & De Geest, S. Moving from the trial to the real world: improving medication adherence using insights of implementation science. Annu. Rev. Pharmacol. Toxicol. 59, 423–445 (2019).
Bonderski, V., Morrow, D. G., Chin, J. & Murray, M. D. Pharmacy-based approach to improving heart failure medication use by older adults with limited health literacy: learning from interdisciplinary experience. Drugs Aging 35, 951–957 (2018).
Nelson, A. J., Bubb, K. & Nicholls, S. J. An update on emerging drugs for the treatment of hypercholesterolemia. Expert Opin. Emerg. Drugs 26, 363–369 (2021).
Kosmas, C. E., Silverio, D., Ovalle, J., Montan, P. D. & Guzman, E. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Prefer. Adherence 12, 2263–2266 (2018).
Zafrir, B., Egbaria, A., Stein, N., Elis, A. & Saliba, W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J. Clin. Lipidol. 15, 202–211. e2 (2021).
Dixon, D. L. & Saseen, J. J. Pharmacist-administered long-acting injectable PCSK9 service: a solution to improve patient access and adherence. J. Am. Pharm. Assoc. 61, e83–e85 (2021).
Million Hearts. Medication Adherence https://millionhearts.hhs.gov/tools-protocols/tools/medication-adherence.html (2022).
Medisafe. https://www.medisafe.com/ (2023).
MyTherapy App https://www.mytherapyapp.com/ (2023).
Express Scripts Pharmacy. Mobile App https://www.express-scripts.com/mobile-app (2023).
Groove Health, Inc. EveryDose App https://www.everydose.ai/download/ (2023).
Sprout. Sprout Care App. https://sprout-apps.com/sprout-care-iphone-app/ (2023).
CareClinic. CareClinic App. https://careclinic.io/.
Montuno Software, Inc. Dosecast Editions App. https://www.montunosoftware.com/dosecast_editions/ (2023).
Author information
Authors and Affiliations
Contributions
A.J.N. and N.J.P. researched data for the article. All the authors discussed its content, wrote the manuscript, and reviewed and edited it before submission.
Corresponding author
Ethics declarations
Competing interests
A.J.N. declares research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company and Novartis Pharmaceuticals and consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company and Novartis. N.J.P. declares research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Duke Clinical Research Institute, Eli Lilly & Company, Novartis Pharmaceuticals, Novo Nordisk Pharmaceutical Company and Verily Sciences Research Company and consulting fees from AstraZeneca, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly & Company, Merck, Novo Nordisk Pharmaceutical Company and Novartis. H.B.B. declares research grants from BeBetter Therapeutics, Boehringer Ingelheim, the Elton John AIDS Foundation, the Hilton Foundation, Improved Patient Outcomes, Merck, NHLBI, Novo Nordisk, Otsuka, Pfizer, Sanofi and Veterans Affairs and consulting fees from Abbott, Imatar, Novartis, Sanofi, Vidya, Walmart and Webmed. H.B.B. is on the Board of Directors of Preventric Diagnostics.
Peer review
Peer review information
Nature Reviews Cardiology thanks Michael Burnier, Ian Kronish and Martin Schulz for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nelson, A.J., Pagidipati, N.J. & Bosworth, H.B. Improving medication adherence in cardiovascular disease. Nat Rev Cardiol 21, 417–429 (2024). https://doi.org/10.1038/s41569-023-00972-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-023-00972-1